Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Alectinib Hydrochloride

FDA-approved product (capsule, oral), marketed as Alecensa.

Registered studies
13
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Alectinib Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anaplastic lymphoma kinase (alk) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

13registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Alectinib Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Alectinib Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms

    NCT05987956 · start 2026-03-18

    Registered record
    Registry ID
    NCT05987956
    Conditions
    ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
    Interventions
    ALECENSA - alectinib hydrochloride capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2026-03-18
    Completion
    2026-12-28
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK-Positive Non-Small Cell Lung Cancer (NSCLC)
    InterventionALECENSA - alectinib hydrochloride capsule
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

    NCT05834348 · start 2023-06-23

    Registered record
    Registry ID
    NCT05834348
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    lorlatinib; crizotinib; brigatinib; ceritinib; alectinib; atezolizumab; bevacizumab; paclitaxel; carboplatin; docetaxel; erlotinib; gefitinib; afatinib; dacomitinib; osimertinib; pembrolizumab; nivolumab; entrectinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-06-23
    Completion
    2024-01-23
    Enrolment
    5,279

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    Interventionlorlatinib; crizotinib; brigatinib; ceritinib +14 more
    PhaseNot recorded
    Registry statusCompleted

  • KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

    NCT05525858 · start 2022-09-28

    Registered record
    Registry ID
    NCT05525858
    Conditions
    Solid Tumor; Advanced Solid Tumor; Metastatic Cancer
    Interventions
    Alectinib; Atezolizumab; Erlotinib; Trastuzumab + Pertuzumab; Trastuzumab emtansine; Vemurafenib; Bevacizumab + Erlotinib; Entrectinib; Pralsetinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-09-28
    Completion
    2027-03
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor; Advanced Solid Tumor; Metastatic Cancer
    InterventionAlectinib; Atezolizumab; Erlotinib; Trastuzumab + Pertuzumab +5 more
    PhaseNot recorded
    Registry statusRecruiting

  • The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

    NCT04591431 · start 2020-10-07

    Registered record
    Registry ID
    NCT04591431
    Conditions
    Breast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer; Other Cancer
    Interventions
    Erlotinib; Trastuzumab; Trastuzumab emtansine; Pertuzumab; Lapatinib; Everolimus; Vemurafenib; Cobimetinib; Alectinib; Brigatinib; Palbociclib; Ponatinib; Vismogedib; Itacitinib; Ipatasertib; Entrectinib; Atezolizumab; Nivolumab; Ipilimumab; Pemigatinib; Oncology Drugs; Pralsetinib; Selpercatinib; Talazoparib; Tepotinib; Alpelisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-10-07
    Completion
    2025-06
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer; Other Cancer
    InterventionErlotinib; Trastuzumab; Trastuzumab emtansine; Pertuzumab +22 more
    PhasePhase 2
    Registry statusUnknown

  • ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

    NCT04341181 · start 2020-08-24

    Registered record
    Registry ID
    NCT04341181
    Conditions
    Cancer; Tumors; Neoplasms; Neoplasia
    Interventions
    Alectinib; Atezolizumab; Avelumab; Axitinib; Erlotinib; Vemurafenib plus Cobimetinib (combination); Trastuzumab plus Pertuzumab (combination); Trastuzumab emtansine; Vismodegib; Niraparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2020-08-24
    Completion
    2030-04-30
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer; Tumors; Neoplasms; Neoplasia
    InterventionAlectinib; Atezolizumab; Avelumab; Axitinib +6 more
    PhasePhase 2
    Registry statusRecruiting

  • PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

    NCT04115410 · start 2020-07-01

    Registered record
    Registry ID
    NCT04115410
    Conditions
    Carcinoma, Non-Small-Cell Lung; Immune-Related Adverse Events
    Interventions
    PD-1 inhibitor; Chemotherapy Drugs, Cancer
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-07-01
    Completion
    2021-12-31
    Enrolment
    4,724

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung; Immune-Related Adverse Events
    InterventionPD-1 inhibitor; Chemotherapy Drugs, Cancer
    PhaseNot recorded
    Registry statusUnknown

  • Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

    NCT04322890 · start 2020-04-16

    Registered record
    Registry ID
    NCT04322890
    Conditions
    Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation; ROS1 Gene Mutation; MET Gene Mutation
    Interventions
    Osimertinib; Alectinib 150 MG; Crizotinib 250 MG; Savolitinib, Crizotinib.; Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2020-04-16
    Completion
    2027-12-24
    Enrolment
    6,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation; ROS1 Gene Mutation +1 more
    InterventionOsimertinib; Alectinib 150 MG; Crizotinib 250 MG; Savolitinib, Crizotinib. +1 more
    PhasePhase 2
    Registry statusRecruiting

  • Brazilian Lung Immunotherapy Study

    NCT05081674 · start 2020-01-01

    Registered record
    Registry ID
    NCT05081674
    Conditions
    Lung Neoplasm
    Interventions
    Alectinib; Pembrolizumab; Nivolumab; Erlotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-01-01
    Completion
    2023-07-30
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Neoplasm
    InterventionAlectinib; Pembrolizumab; Nivolumab; Erlotinib
    PhasePhase 2
    Registry statusCompleted

  • A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

    NCT03498521 · start 2018-07-10

    Registered record
    Registry ID
    NCT03498521
    Conditions
    Cancer of Unknown Primary Site
    Interventions
    Alectinib; Vismodegib; Ipatasertib; Olaparib; Erlotinib; Bevacizumab; Vemurafenib; Cobimetinib; Trastuzumab Subcutaneous (SC); Pertuzumab; Atezolizumab; Carboplatin; Paclitaxel; Cisplatin; Gemcitabine; Entrectinib; Ivosidenib; Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-07-10
    Completion
    2024-11-07
    Enrolment
    529

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer of Unknown Primary Site
    InterventionAlectinib; Vismodegib; Ipatasertib; Olaparib +14 more
    PhasePhase 2
    Registry statusCompleted

  • The Drug Rediscovery Protocol (DRUP Trial)

    NCT02925234 · start 2016-08

    Registered record
    Registry ID
    NCT02925234
    Conditions
    Cancer; Tumors; Neoplasm; Neoplasia
    Interventions
    Panitumumab; Olaparib; Dabrafenib; Nilotinib; Trametinib; Erlotinib; Trastuzumab and Pertuzumab (combination treatment); Vemurafenib and Cobimetinib (combination treatment); Vismodegib; Regorafenib; Nivolumab; Afatinib; Dabrafenib and trametinib; Ribociclib; Lenvatinib; Pembrolizumab; Durvalumab; Rucaparib; Axitinib; Palbociclib; Crizotinib; Sunitinib; Cabozantinib; Abemaciclib; Alectinib; Atezolizumab and Bevacizumab; Ipilimumab and nivolumab; Entrectinib; Talazoparib; Dacomitinib; Lorlatinib; Erdafitinib; Alpelisib; Niraparib; Pemigatinib; Selpercatinib; Tepotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2016-08
    Completion
    2027-12
    Enrolment
    1,550

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer; Tumors; Neoplasm; Neoplasia
    InterventionPanitumumab; Olaparib; Dabrafenib; Nilotinib +33 more
    PhasePhase 2
    Registry statusRecruiting

  • My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

    NCT02091141 · start 2014-04-14

    Registered record
    Registry ID
    NCT02091141
    Conditions
    Neoplasms; Solid Tumors; Biliary Cancer; Salivary Cancer; Bladder Cancer
    Interventions
    Trastuzumab; Pertuzumab; Erlotinib; Vemurafenib; Cobimetinib; Vismodegib; Alectinib; Atezolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-04-14
    Completion
    2023-05-24
    Enrolment
    673

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms; Solid Tumors; Biliary Cancer; Salivary Cancer +1 more
    InterventionTrastuzumab; Pertuzumab; Erlotinib; Vemurafenib +4 more
    PhasePhase 2
    Registry statusCompleted

  • A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

    NCT02013219 · start 2014-04-03

    Registered record
    Registry ID
    NCT02013219
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Alectinib; Atezolizumab; Erlotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-04-03
    Completion
    2020-02-05
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionAlectinib; Atezolizumab; Erlotinib
    PhasePhase 1
    Registry statusCompleted

  • A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment

    NCT01801111 · start 2013-06-20

    Registered record
    Registry ID
    NCT01801111
    Conditions
    Non-Small-Cell Lung Carcinoma
    Interventions
    Erlotinib; Alectinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2013-06-20
    Completion
    2017-10-27
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small-Cell Lung Carcinoma
    InterventionErlotinib; Alectinib
    PhasePhase 1 / Phase 2
    Registry statusCompleted